B-Cell Lymphomas Pipeline Insights, Treatment Drugs, Clinical Trials and Companies 2024 (Updated)

DelveInsight's, "B-cell Lymphoma- Pipeline Insight, 2024" report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in B-Cell Lymphomas Research. Learn more about our innovative pipeline today! @ B-Cell Lymphomas Pipeline Outlook- https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the B-Cell Lymphomas Pipeline Report
• In December 2024:- Incyte Corporation- The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).
• In December 2024:- Celgene- The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
• In December 2024:- Hoffmann-La Roche-The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
• DelveInsight's B-Cell Lymphomas pipeline report depicts a robust space with 295+ active players working to develop 300+ pipeline therapies for B-Cell Lymphomas treatment.
• The leading B-Cell Lymphomas Companies such as Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc, Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences HUTCHMED, and others.
• Promising B-Cell Lymphomas Therapies such as HLX01, Rituximab, CHOP, Tafasitamab, Lenalidomide, Golcadomide, and others.

Stay informed about the cutting-edge advancements in B-Cell Lymphomas treatments. Download for updates and be a part of the revolution in care @ B-Cell Lymphomas Clinical Trials Assessment- https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

B-Cell Lymphomas Emerging Drugs Profile

• Lisocabtagene maraleucel: Bristol Myers Squibb
Lisocabtagene maraleucelis a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells. It is made from a patient's own T cells, which are collected and genetically reengineered to become CAR T cells that are then delivered via infusion as a one-time treatment. Breyanzi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal LBCL, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy, or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplant due to comorbidities or age, or relapsed or refractory disease after two or more lines of systemic therapy. The drug is currently in Phase III stage of development for treatment of B cell lymphoma.

• Glofitamab: Hoffmann-La Roche
Glofitamab is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T-cells and CD20 on the surface of B-cells. The drug candidate was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T-cells, a type of immune cell, and two regions that bind to CD20, a protein on B-cells, which can be healthy or malignant. This dual-targeting brings the T-cell in close proximity to the B-cell, activating the release of cancer cell-killing proteins from the T-cell. Columvi is part of Roche's broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development programme that also includes Lunsumio® (mosunetuzumab), which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems. Roche is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma (DLBCL) and other blood cancers. The drug is currently in Phase III stage of development for treatment of B cell lymphoma.

• NKTR-255: Nektar Therapeutics
NKTR-255 is an investigational drug developed by Nektar Therapeutics, designed as a polymer-conjugated interleukin-15 (IL-15) receptor agonist. Its primary goal is to enhance the immune system's capacity to combat cancer by boosting the proliferation and survival of natural killer (NK) cells and memory CD8+ T cells. This mechanism involves engaging the entire IL-15 receptor complex, which may lead to the formation of long-term immunological memory and a sustained anti-tumor immune response. The drug is currently in Phase II/III stage of development for treatment of B cell lymphoma.

• Zamtocabtagene autoleucel: Miltenyi Biomedicine GmbH
Zamtocabtagene autoleucel, also known as MB-CART2019.1, is an investigational chimeric antigen receptor T-cell (CAR-T) therapy developed by Miltenyi Biotec. This therapy targets both CD19 and CD20 antigens, making it a bispecific treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Zamtocabtagene autoleucel is designed to enhance the immune response against B-cell tumors by utilizing genetically modified T cells that express CARs targeting both CD19 and CD20. The therapy employs a lentiviral vector to transduce autologous T cells, which are then expanded and infused back into the patient after lymphodepleting chemotherapy. This dual targeting approach aims to overcome resistance mechanisms associated with single-target therapies, particularly in cases where the tumor may lose expression of one of the targets. The drug is currently in Phase II stage of development for treatment of B cell lymphoma.

• MB-CART20.1: Miltenyi Biomedicine GmbH
MB-CART20.1 is an investigational CAR-T cell therapy engineered to target the CD20 protein, which is highly expressed on the surface of B-cells in certain cancers, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. By modifying a patient's T-cells to express chimeric antigen receptors (CARs) that recognize CD20, MB-CART20.1 enables the immune system to selectively attack and eliminate cancerous B-cells. This therapy is designed to offer a novel option for patients with relapsed or refractory CD20-positive malignancies, aiming to improve outcomes through enhanced tumor targeting and prolonged remission. Clinical trials are ongoing to assess its efficacy and safety. The drug is currently in Phase I/II stage of development for treatment of B cell lymphoma.

• AVM0703: AVM Biotechnology
AVM0703 is a clinical-stage therapeutic that works by rapidly inducing the production and release of endogenous bispecific gamma delta TCR+ and invariant TCR+ Natural Killer T-like cells (AVM-NKT), which possess unique immune properties. Following a single dose of AVM0703, these supercharged immune cells appear in the bloodstream and target abnormal cells, including cancer cells, infected cells, and autoreactive lymphocytes. AVM0703's mechanism is based on a proprietary suprapharmacologic dose of dexamethasone, designed to deliver high doses without typical side effects. This enhanced dexamethasone formulation triggers the activation and mobilization of AVM-NKT cells, offering a potent yet gentler treatment option by targeting malignancies and immune disorders with precision. The drug is currently in Phase I/II stage of development for treatment of B cell lymphoma.

• LBS-007: Lin BioScience, Inc
LBS-007 is a novel targeted therapy for the treatment of a broad array of cancers. It has demonstrated activity against leukemia and solid tumors, especially in chemotherapy-resistant cell lines and other cancer cell lines. LBS-007 has obtained Orphan Drug Destination (ODD) for Acute Lymphoma Leukemia (ALL) from US FDA in 2018/March and entered a first-in-human Phase I/II trial. LBS-007 inhibits cancer cell replication by interrupting the S phase of the cell cycle. Its mechanism of action is to inhibit a key regulator protein of the cell cycle, CDC7. Inhibition of CDC7 stops the proliferation of tumor cells and results in cancer cell death. Because CDC7's activity is often upregulated in cancer cells in comparison to healthy cells, it's an ideal candidate for a targeted anti-cancer therapy. The drug is currently in Preclinical stage of development for treatment of B cell lymphoma.

Learn more about B-Cell Lymphomas Drugs opportunities in our groundbreaking B-Cell Lymphomas Research and development projects @ B-Cell Lymphomas Unmet Needs- https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

B-Cell Lymphomas Companies
Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc, Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences HUTCHMED, and others.

B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

B-Cell Lymphomas Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in B-Cell Lymphomas treatment by visiting our website. Stay informed about how we're transforming the future of disease @ B-Cell Lymphomas Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the B-Cell Lymphomas Pipeline Report
• Coverage- Global
• B-Cell Lymphomas Companies- Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc, Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences HUTCHMED, and others.
• B-Cell Lymphomas Therapies- HLX01, Rituximab, CHOP, Tafasitamab, Lenalidomide, Golcadomide, and others.
• B-Cell Lymphomas Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• B-Cell Lymphomas Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of B-Cell Lymphomas Pipeline on our website @ B-Cell Lymphomas Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. B-Cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. B-Cell Lymphoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Lisocabtagene maraleucel: Bristol Myers Squibb
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Zamtocabtagene autoleucel: Miltenyi Biomedicine GmbH
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. MB-CART20.1: Miltenyi Biomedicine GmbH
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. LBS-007: Lin BioScience, Inc
18. Drug profiles in the detailed report…..
19. Inactive Products
20. B-Cell Lymphoma Key Companies
21. B-Cell Lymphoma Key Products
22. B-Cell Lymphoma- Unmet Needs
23. B-Cell Lymphoma- Market Drivers and Barriers
24. B-Cell Lymphoma- Future Perspectives and Conclusion
25. B-Cell Lymphoma Analyst Views
26. B-Cell Lymphoma Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2024

attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
external defibrillators market- https://www.delveinsight.com/report-store/external-defibrillators-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
ornithine transcarbamylase deficiency market- https://www.delveinsight.com/report-store/ornithine-transcarbamylase-deficiency-otc-deficiency-market
pediatric neuroblastoma market- https://www.delveinsight.com/report-store/neuroblastoma-market
schistosomiasis market- https://www.delveinsight.com/report-store/schistosomiasis-market
tcr therapy market- https://www.delveinsight.com/report-store/tcr-therapy-market
uk healthcare report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
vascular access devices market https://www.delveinsight.com/report-store/vascular-access-device-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
artificial disc market- https://www.delveinsight.com/report-store/artificial-disc-market
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
overactive bladder syndrome market- https://www.delveinsight.com/report-store/overactive-bladder-market
respiratory syncytial virus market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
shingles market - https://www.delveinsight.com/report-store/shingles-market
short bowel syndrome drug market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
cxcr inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
short bowel syndrome market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
catheter stabilization devices market- https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
celiac disease market- https://www.delveinsight.com/blog/celiac-disease-market-key-companies
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
pulmonary emphysema market- https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-treatment-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
nk cell therapy market- https://www.delveinsight.com/blog/nk-cell-therapy-in-cancer-treatment
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
healthcare consulting solutions- https://www.delveinsight.com/consulting
skin neoplasm market- https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
meibomian gland dysfunction market- https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight
dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-epidemiology-forecast-insight
testicular neoplasm market- https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market
microscopy device market- https://www.delveinsight.com/sample-request/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.